Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.

Slides:



Advertisements
Similar presentations
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Advertisements

Extending life for women with HER2-positive MBC
Our bold approach to life-changing medicines
Metastatic HER2-Positive Breast Cancer: Treatment Selection and Sequencing in the First Line and Beyond Moderator: Joseph Gligorov, MD, PhD Head, Cancer.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Key Issues in the Management of Metastatic Breast Cancer Case 2 (HER2 positive), v5 - July 3, to Abraxis Medical.
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Assistant Professor of Medicine Dana-Farber Cancer Institute
Drug Treatment of Metastatic Breast Cancer
New Evidence reports on presentations given at ASCO 2012
AVADO PFS Analysis (ITT Population) All P values vs. placebo Adapted from Miles et al. ASCO 2008, abstract LBA 1011.
Xeloda and Xeloda-based combinations in the treatment of MBC Steffan Kahlert Insert affiliation.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Placebo + Trastuzumab + Docetaxel vs.
Malattia HER-2 positiva Terapia per la fase metastatica Cosa sapremo presto: nuovi farmaci U.O. di Oncologia Medica “Sandro Pitigliani” Dipartimento di.
Bevacizumab: Antiangiogenic therapy for breast cancer: where do we stand? Fortunato Ciardiello Division of Medical Oncology, Department of Clinical and.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.
Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.
Use of Chemotherapeutic and Biologic Agents in Metastatic Breast Cancer Breast Cancer Update Medical Oncology Educational Forum May 21, 2005 Kathy D Miller.
OLD AND NEW ANTHACYCLINES: A STILL VALID OPTION IN BREAST CANCER TREATMENT True: Clara Natoli.
Assistant Professor of Medicine Dana-Farber Cancer Institute
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
Abstract Introduction  What is a Herceptin (Trastuzumab) ?  Herceptin (Trastuzumab) is an monoclonal antibody,it is an example of targeted therapy an.
CAELYX CLINICAL TRIALS Metastatic Breast Cancer (MBC)
Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results.
Sunil Verma MD, MSEd, FRCPC Medical Oncologist
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Axel Grothey, MD Professor of Oncology Mayo Clinic Rochester, Minnesota Strategies to Improve Patient Outcomes in Gastric and Gastroesophageal Junction.
Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.
Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831.
E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
Pritchard KI et al. Proc SABCS 2010;Abstract P
HER-2 targeting: dalla malattia avanzata alla fase pre-operatoria
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO.
Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.
Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )
Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.
BACKGROUND & STUDY AIMS TARGETED CHEMOTHERAPY WITH ALBUMIN-BOUND PACLITAXEL (NAB-PACLITAXEL) FOR METASTATIC BREAST CANCER (MBC): WHICH BENEFIT FOR WHICH.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
Slamon D et al. SABCS 2009;Abstract 62.
Alessandra Gennari, MD PhD
Chicago 2008: Post - ASCO Analysis: Metastatic Breast Cancer
Phase II Study of Docetaxel (D) and Oxaliplatin (O) in Recurrent Metastatic Transitional Cell Carcinoma of the Bladder Davar D1, Appleman LA1, Friedland.
Gajria D et al. Proc SABCS 2010;Abstract P
Biologika bei onkologischen Erkrankungen älterer Menschen
DR VANDERPUYE CONSULTANT RADIATION AND CLINICAL ONCOLOGIST GHANA
Vahdat L et al. Proc SABCS 2012;Abstract P
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
Swain SM et al. Proc SABCS 2012;Abstract P
Barrios C et al. SABCS 2009;Abstract 46.
Krop I et al. SABCS 2009;Abstract 5090.
Jones SE et al. SABCS 2009;Abstract 5082.
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
Baselga J et al. SABCS 2009;Abstract 45.
Response Rates and Adverse Event Rates in Phase II Trial
Presentation transcript:

Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert

Herceptin ® in metastatic breast cancer HER2-positive breast cancer is an aggressive cancer and is associated with a poor prognosis Herceptin ® is currently licensed for the treatment of HER2-positive metastatic breast cancer (MBC) –first-line in combination with docetaxel in patients with no prior chemotherapy for MBC –first-line in combination with paclitaxel in patients who have received prior anthracyclines or for whom an anthracyline is not suitable –as monotherapy in patients who have received prior treatment for MBC

Herceptin ® plus docetaxel (M77001)

Herceptin ® plus docetaxel (M77001): trial design HER2-positive MBC (IHC 3+ and/or FISH+) n=188 Docetaxel* 100mg/m 2 q3w x 6 Docetaxel 100mg/m 2 q3w x 6 Herceptin ® 4mg/kg loading,  2mg/kg weekly until PD + *Patients progressing on docetaxel alone could crossover to receive Herceptin ® Two patients did not receive study medication n=92 n=94 Marty M, et al. J Clin Oncol 2005;23:4265–74

Herceptin ® plus docetaxel (M77001): inclusion criteria MBC –measurable disease HER2-positive –IHC 3+ and/or FISH+ –IHC 2+ initially allowed (July 1999–August 2000) ECOG  2 Life expectancy  12 weeks LVEF >50% Adequate bone marrow, hepatic and renal function Prior chemotherapy –none for MBC –no prior taxanes or anti-HER therapy Marty M, et al. J Clin Oncol 2005;23:4265–74

Herceptin ® plus docetaxel (M77001): patient demographics *Eight patients IHC 2+/FISH–; one patient IHC 0/1+/FISH unknown (docetaxel alone) Marty M, et al. J Clin Oncol 2005;23:4265–74

Herceptin ® plus docetaxel (M77001): patient demographics Marty M, et al. J Clin Oncol 2005;23:4265–74

Herceptin ® plus docetaxel (M77001): OS at 24 months Intent-to-treat population, 24-month cut-off Documented crossover = 57% Estimated probability Months 8.5 months Herceptin ® + docetaxel Docetaxel alone Marty M, et al. J Clin Oncol 2005;23:4265–74

Herceptin ® plus docetaxel (M77001): OS at 24 months Intent-to-treat population, 24-month cut-off Estimated probability Months Herceptin ® + docetaxel (n=92) Docetaxel alone/crossover (n=45) Docetaxel alone (n=49) Marty M, et al. J Clin Oncol 2005;23:4265–74

Herceptin ® plus docetaxel (M77001): efficacy 24 month follow up Marty M, et al. J Clin Oncol 2005;23:4265–74

Herceptin ® plus docetaxel (M77001): non-haematological toxicity (grade 3/4) Adverse events occurring in ≥5% and congestive heart failure (CHF) Marty M, et al. J Clin Oncol 2005;23:4265–74

Herceptin ® plus docetaxel (M77001): haematological toxicity (grade 3/4) Marty M, et al. J Clin Oncol 2005;23:4265–74

Herceptin ® plus docetaxel (M77001): conclusions Adding Herceptin ® to docetaxel improves all clinical outcomes parameters –ORR (from 34 to 61%) –TTP (from 6.1 to 11.7 months) –OS (from 22.7 to 31.2 months) Herceptin ® adds little to the toxicity profile of docetaxel Herceptin ® plus docetaxel should be used upfront for greatest clinical benefit in patients with HER2-positive MBC These 24-month data provide evidence of a long-term survival benefit following the addition of Herceptin ® to docetaxel

Herceptin ® plus paclitaxel (H0648g)

Herceptin ® plus paclitaxel (H0648g): design and enrolment No prior anthracyclinesPrior anthracyclines Paclitaxel (n=96) Herceptin ® + paclitaxel (n=92) AC (n=138) Herceptin ® + AC (n=143) MBC HER2 IHC 2+/3+ (CTA) No prior CT for MBC Measurable disease KPS  60% Patients (n=469) Slamon DJ, et al. N Engl J Med 2001;334:783–92

Herceptin ® plus paclitaxel (H0648g): treatment plan Chemotherapy q3w x 6 –AC = doxorubicin (60mg/m 2 ) or epirubicin (75mg/m 2 ) + cyclophosphamide (600mg/m 2 ) –Paclitaxel (175mg/m 2 ) Herceptin ® –4mg/kg loading, 2mg/kg qw until PD Slamon DJ, et al. N Engl J Med 2001;334:783–92

Herceptin ® plus paclitaxel (H0648g): demographics Slamon DJ, et al. N Engl J Med 2001;334:783–92

Herceptin ® plus paclitaxel (H0648g): prior therapy Slamon DJ, et al. N Engl J Med 2001;334:783–92

*p<0.05 Herceptin ® plus paclitaxel (H0648g): efficacy (all patients) Slamon DJ, et al. N Engl J Med 2001;334:783–92

Herceptin ® + chemotherapy Chemotherapy Time (months) Probability p= Herceptin ® plus paclitaxel (H0648g): TTP Slamon DJ, et al. N Engl J Med 2001;334:783–92

Herceptin ® plus paclitaxel (H0648g): OS (all patients) Slamon DJ, et al. N Engl J Med 2001;334:783–92 Crossover 72%

Herceptin ® plus paclitaxel (H0648g): summary of SAEs Slamon DJ, et al. N Engl J Med 2001;344:783–92

Herceptin ® plus paclitaxel (H0648g): summary of cardiac safety Suter T, et al. Breast 2004;13:173–83

*p< :n=349 All:n=469 Slamon DJ, et al. N Engl J Med 2001;344:783–92 Baselga J. Oncology 2001;61 (Suppl 2):15–21 Herceptin ® plus paclitaxel (H0648g): efficacy (IHC 3+ versus all)

Herceptin ® plus paclitaxel (H0648g): conclusions Adding Herceptin ® to paclitaxel improves all clinical outcome parameters –ORR (from 17 to 49%*) –TTP (from 3 to 7 months*) –OS (from 18 to 25 months*) Herceptin ® adds little to the toxicity profile of paclitaxel Herceptin plus paclitaxel should be considered as first-line therapy in HER2-positive MBC *IHC 3+ patients

Other Herceptin ® trials in MBC

Phase II Herceptin ® plus vinorelbine: efficacy Vinorelbine (n=33) Vinorelbine + Herceptin (n=35) Overall response (%) 27.3 (95% CI 12.1, 42.5) 51.4 (95% CI 32.9, 68) Complete response (%) Partial response (%) Stable disease (%) Progressive disease Median TTP (months) 6.0 (95% CI: 4, 8)9.0 (95% CI: 7, 11) Median OS (months) 22 (95% CI: 12, 32)27 (95% CI: 19, 35) Papaldo P, et al. Ann Oncol 2006

Phase II Herceptin ® plus vinorelbine: safety Toxicity (Grade 3/4) (%)Vinorelbine (n=33)Vinorelbine + Herceptin (n=35) Leucopenia3- Neutropenia5149 Febrile neutropenia6- Anaemia63 Thrombocytopenia3- Nausea/vomiting-- Mucositis3- Peripheral neuropathy-- Liver-- Diarrhoea3- Stipsis-- Cardiac toxicity-3 Papaldo P, et al. Ann Oncol 2006

Herceptin ® q3w: rationale Ghahramani P, et al. The Breast 2003;12(Suppl. 1):S40 (Abstract P89) 1, Serum concentration (µg/mL) Time (weeks) 3-weekly regimen Weekly regimen

Herceptin q3w plus paclitaxel(BO15935) Leyland-Jones B, et al. J Clin Oncol 2003;21:3965–71

Herceptin ® monotherapy trials in MBC H0650gWO16229H0649g Line of therapy First Second/third Regimen 4mg/kg LD, 2mg/kg qw or 8mg/kg LD, 4mg/kg qw 8mg/kg LD, 6mg/kg q3w 4mg/kg LD, 2mg/kg qw No of patients 11483*222 ORR (%) Overall IHC 3+ 35NR18 IHC 2+ 0NA6 FISH positive 34NR19 FISH negative 7NR0 TTP (months) 3.5, 3.8 † DR (months) NR OS (months 24.4NR13 LD=loading dose; NR=not recorded; NA=not applicable; qw=weekly; q3w= every 3 weeks *Results from per protocol subset † TTP given for standard and higher Herceptin ® dose regimens, respectively

Summary: Herceptin ® combinations in MBC 1 Slamon DJ, et al. N Engl J Med 2001;344:783–92 2 Leyland-Jones B, et al. J Clin Oncol 2003;21:3965–71 3 Marty M, et al. J Clin Oncol 2005;23: Papaldo P, et al. Ann Oncol 2006 H0648g 1 BO M H + P P aloneH + PH + D D aloneH + V 4 V alone 4 ORR (%) TTP (months) OS (months) NR NR=not recorded H=Herceptin ® ; P=paclitaxel; D=docetaxel; V=vinorelbine

Herceptin ® in MBC: conclusions In metastatic breast cancer patients –Herceptin ® in combination with chemotherapy leads to an improvement in survival compared to chemotherapy alone adverse events associated with chemotherapy are not exacerbated by addition of Herceptin ® –Herceptin ® monotherapy has also been shown to be effective Cardiac events are reversible and manageable –the rate of asymptomatic cardiac events in clinical trials has fallen to 2% based on selection criteria and cardiac monitoring